Literature DB >> 30258545

Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS.

Jason R Abbott1, Pratiq A Patel1, Jennifer E Howes1, Denis T Akan1, J Phillip Kennedy1, Michael C Burns1, Carrie F Browning1, Qi Sun1, Olivia W Rossanese1, Jason Phan1, Alex G Waterson1,2, Stephen W Fesik1,1,2.   

Abstract

Proteins in the RAS family are important regulators of cellular signaling and, when mutated, can drive cancer pathogenesis. Despite considerable effort over the last 30 years, RAS proteins have proven to be recalcitrant therapeutic targets. One approach for modulating RAS signaling is to target proteins that interact with RAS, such as the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). Here, we report hit-to-lead studies on quinazoline-containing compounds that bind to SOS1 and activate nucleotide exchange on RAS. Using structure-based design, we refined the substituents attached to the quinazoline nucleus and built in additional interactions not present in the initial HTS hit. Optimized compounds activate nucleotide exchange at single-digit micromolar concentrations in vitro. In HeLa cells, these quinazolines increase the levels of RAS-GTP and cause signaling changes in the mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK) pathway.

Entities:  

Year:  2018        PMID: 30258545      PMCID: PMC6142059          DOI: 10.1021/acsmedchemlett.8b00296

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  21 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

Review 3.  Improving Prospects for Targeting RAS.

Authors:  Harshabad Singh; Dan L Longo; Bruce A Chabner
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

Review 4.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

Review 5.  Reactive metabolites in the biotransformation of molecules containing a furan ring.

Authors:  Lisa A Peterson
Journal:  Chem Res Toxicol       Date:  2012-10-24       Impact factor: 3.739

6.  Escape from flatland: increasing saturation as an approach to improving clinical success.

Authors:  Frank Lovering; Jack Bikker; Christine Humblet
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

8.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

9.  High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling.

Authors:  Michael C Burns; Jennifer E Howes; Qi Sun; Andrew J Little; DeMarco V Camper; Jason R Abbott; Jason Phan; Taekyu Lee; Alex G Waterson; Olivia W Rossanese; Stephen W Fesik
Journal:  Anal Biochem       Date:  2018-02-11       Impact factor: 3.365

10.  Small Molecule-Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1.

Authors:  Jennifer E Howes; Denis T Akan; Michael C Burns; Olivia W Rossanese; Alex G Waterson; Stephen W Fesik
Journal:  Mol Cancer Ther       Date:  2018-02-13       Impact factor: 6.261

View more
  2 in total

1.  Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.

Authors:  Timothy R Hodges; Jason R Abbott; Andrew J Little; Dhruba Sarkar; James M Salovich; Jennifer E Howes; Denis T Akan; Jiqing Sai; Allison L Arnold; Carrie Browning; Michael C Burns; Tammy Sobolik; Qi Sun; Yugandhar Beesetty; Jesse A Coker; Dirk Scharn; Heinz Stadtmueller; Olivia W Rossanese; Jason Phan; Alex G Waterson; Darryl B McConnell; Stephen W Fesik
Journal:  J Med Chem       Date:  2018-09-28       Impact factor: 7.446

2.  Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.

Authors:  John M Ketcham; Jacob Haling; Shilpi Khare; Vickie Bowcut; David M Briere; Aaron C Burns; Robin J Gunn; Anthony Ivetac; Jon Kuehler; Svitlana Kulyk; Jade Laguer; J David Lawson; Krystal Moya; Natalie Nguyen; Lisa Rahbaek; Barbara Saechao; Christopher R Smith; Niranjan Sudhakar; Nicole C Thomas; Laura Vegar; Darin Vanderpool; Xiaolun Wang; Larry Yan; Peter Olson; James G Christensen; Matthew A Marx
Journal:  J Med Chem       Date:  2022-07-14       Impact factor: 8.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.